Compounds > 2'-methyl-2'-deoxycytidine

Page last updated: 2024-11-07

2'-methyl-2'-deoxycytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2'-methyl-2'-deoxycytidine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	130783
CHEMBL ID	225276
SCHEMBL ID	5709901
MeSH ID	M0155119

Synonyms (15)

Synonym
2'-deoxy-2'-c-methylcytidine
2'-methyl-2'-deoxycytidine
2'-deoxy-2'-methylcytidine
115494-53-6
2-c-ethynyl-cytidine
4-amino-1-[(2r,3r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-2-yl]pyrimidin-2-one
2',2'-dmc
CHEMBL225276
2'c-me-dc
4-amino-1-[(2r,3r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one
SCHEMBL5709901
DTXSID70151114
2/'-methyl-2/'-deoxycytidine
A901619
4-amino-1-[(2r,3r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methyl-tetrahydrofuran-2-yl]pyrimidin-2-one; 4-amino-1-[(2r,3r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methyl-2-tetrahydrofuranyl]-2-pyrimidinone; 4-amino-1-[(2r,3r,4s,5r)-4-hydroxy-3-methyl-5-methylol-t

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Deoxycytidine kinase	Homo sapiens (human)	Km	46.2000	0.4000	3.5790	8.5000	AID278932
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Process	via Protein(s)	Taxonomy
pyrimidine nucleotide metabolic process	Deoxycytidine kinase	Homo sapiens (human)
CMP biosynthetic process	Deoxycytidine kinase	Homo sapiens (human)
dAMP salvage	Deoxycytidine kinase	Homo sapiens (human)
nucleoside phosphate biosynthetic process	Deoxycytidine kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Process	via Protein(s)	Taxonomy
deoxyadenosine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
deoxycytidine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
deoxyguanosine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
ATP binding	Deoxycytidine kinase	Homo sapiens (human)
protein homodimerization activity	Deoxycytidine kinase	Homo sapiens (human)
cytidine kinase activity	Deoxycytidine kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Process	via Protein(s)	Taxonomy
nucleoplasm	Deoxycytidine kinase	Homo sapiens (human)
cytosol	Deoxycytidine kinase	Homo sapiens (human)
mitochondrion	Deoxycytidine kinase	Homo sapiens (human)
cytoplasm	Deoxycytidine kinase	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay ID	Title	Year	Journal	Article
AID278932	Activity of human dCK expressed in HepG2 cells assessed as phosphorylation by coupled enzyme assay	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID278933	Ratio of Kcat to Km for human dCK expressed in HepG2 cells	2007	Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2	Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID99488	Concentration required for 50% inhibition of cell growth of L1210 leukemic cell lines in mouse.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Nucleosides and nucleotides. 94. Radical deoxygenation of tert-alcohols in 1-(2-C-alkylpentofuranosyl) pyrimidines: synthesis of (2'S)-2'-deoxy-2'-C-methylcytidine, an antileukemic nucleoside.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (12.50)	18.7374
1990's	1 (12.50)	18.2507
2000's	4 (50.00)	29.6817
2010's	1 (12.50)	24.3611
2020's	1 (12.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	25.72 (24.57)
Research Supply Index	2.20 (2.92)
Research Growth Index	4.83 (4.65)
Search Engine Demand Index	23.28 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (25.72)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	8 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	1.97	1	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
uridine [no description available]	2.96	4	0	uridines	drug metabolite; fundamental metabolite; human metabolite
uridine monophosphate Uridine Monophosphate: 5'-Uridylic acid. A uracil nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. uridine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having uracil as the nucleobase.	2.03	1	0	pyrimidine ribonucleoside 5'-monophosphate; uridine 5'-phosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
cytidine monophosphate Cytidine Monophosphate: Cytidine (dihydrogen phosphate). A cytosine nucleotide containing one phosphate group esterified to the sugar moiety in the 2', 3' or 5' position.. cytidine 5'-monophosphate : A pyrimidine ribonucleoside 5'-monophosphate having cytosine as the nucleobase.	2.03	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-monophosphate	Escherichia coli metabolite; human metabolite; mouse metabolite
cytidine diphosphate Cytidine Diphosphate: Cytidine 5'-(trihydrogen diphosphate). A cytosine nucleotide containing two phosphate groups esterified to the sugar moiety. Synonyms: CRPP; cytidine pyrophosphate.	2.03	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-diphosphate	Escherichia coli metabolite; mouse metabolite
uridine triphosphate Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety.	2.03	1	0	pyrimidine ribonucleoside 5'-triphosphate; uridine 5'-phosphate	Escherichia coli metabolite; mouse metabolite
cytidine [no description available]	2.71	3	0	cytidines	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
cytidine triphosphate Cytidine Triphosphate: Cytidine 5'-(tetrahydrogen triphosphate). A cytosine nucleotide containing three phosphate groups esterified to the sugar moiety.	2.03	1	0	cytidine 5'-phosphate; pyrimidine ribonucleoside 5'-triphosphate	Escherichia coli metabolite; mouse metabolite
cytarabine [no description available]	1.97	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
deoxycytidine [no description available]	3.52	8	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
deoxycytidine monophosphate Deoxycytidine Monophosphate: Deoxycytidine (dihydrogen phosphate). A deoxycytosine nucleotide containing one phosphate group esterified to the deoxyribose moiety in the 2'-,3'- or 5- positions.. 2'-deoxycytosine 5'-monophosphate : A pyrimidine 2'-deoxyribonucleoside 5'-monophosphate having cytosine as the nucleobase.	2.03	1	0	2'-deoxycytidine phosphate; pyrimidine 2'-deoxyribonucleoside 5'-monophosphate	Escherichia coli metabolite; mouse metabolite
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	2.03	1	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
2'-fluoro-2'-deoxycytidine [no description available]	2.03	1	0
hydroxyl radical Hydroxyl Radical: The univalent radical OH. Hydroxyl radical is a potent oxidizing agent.	2.02	1	0	oxygen hydride; oxygen radical; reactive oxygen species
2'-c-methylcytidine 2'-C-methylcytidine: structure in first source	2.4	2	0
psi 6130 2'-deoxy-2'-fluoro-2'-C-methylcytidine: PSI-6130 is the (beta-D)-isomer; has antiviral activity against hepatitis C virus; structure in first source	2.03	1	0
oligonucleotides [no description available]	2.15	1	0

Condition	Indicated	Relationship Strength	Studies	Trials
Leucocythaemia [description not available]	0	1.97	1	0
Leukemia L 1210 [description not available]	0	2.38	2	0
Benign Neoplasms [description not available]	0	1.97	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	0	1.97	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	1.97	1	0
Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted [description not available]	0	2.03	1	0
Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.	0	2.03	1	0